Month: November 2022

On January 6, 2012, Jacolot, Maiwenn; Jean, Mickael; Levoin, Nicolas; van de Weghe, Pierre published an article.Product Details of 3976-69-0 The title of the article was The Prins Reaction Using Ketones: Rationalization and Application toward the Synthesis of the Portentol Skeleton. And the article contained the following:

We report a TMSI-promoted Prins cyclization reaction with ketones as carbonyl partners to prepare polysubstituted chiral spirotetrahydropyrans. In the presence of racemic 2-methylcyclohexanone a dynamic kinetic resolution occurred affording one stereoisomer. The observed enantiospecificity has been rationalized by DFT calculation The experimental process involved the reaction of (R)-Methyl 3-hydroxybutanoate(cas: 3976-69-0).Product Details of 3976-69-0

The Article related to crystal mol structure nitro oxaspiro undecanyl benzamide, chiral spiropyran portentol skeleton preparation, dft mechanism calculation prins cyclization ketone, Heterocyclic Compounds (One Hetero Atom): Spiro Compounds With One Hetero Atom In Each Ring and other aspects.Product Details of 3976-69-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 29, 2018, Bellenie, Benjamin Richard; Cheung, Kwai Ming Jack; Davis, Owen Alexander; Hoelder, Swen; Huckvale, Rosemary; Lloyd, Matthew Garth published a patent.Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate The title of the patent was Preparation of 4,6-diamino-quinolin-2(1H)-one derived inhibitors of Bcl6 for treatment of cancer. And the patent contained the following:

The invention relates to compounds of formula I that function as inhibitors of Bcl6 (B-cell lymphoma 6) useful for treatment of disorders involving Bcl6 activity such as proliferative disorders including cancers. Addnl., the invention comprises synthetic processes for the preparation of I and pharmaceutical compositions containing I. Compounds of formula I [wherein X1 = N, CH, C-alkyl, C-halo, etc.; X2 and X3 independently = N, CH, CF, CCl, etc.; R1 = H, CH3, 2-(methoxyethoxy)ethyl, etc.; R2 = 2,3-dichloro-pyridin-4-yl, 2-chloro-4-cyano-pyridin-4-yl, 2-chloro-5-methoxy-pyrimidin-4-yl, etc.; R3 = H, C1-2 alkyl, cyano, etc.; R4 = cyano, C1-4 alkyl, C1-4 haloalkyl, etc.; R5 = H, C1-4 alkyl, cyano, nitro, acetylenyl, Ph, etc.; with provisos] and pharmaceutically acceptable salts or solvates thereof, are claimed and exemplified. Example compound II was prepared from the reaction of 6-amino-1-methyl-4-[(1-methyl-1-pyrimidin-2-ylethyl)amino]quinolin-2-one and 2,4-dichloropyridine-3-carbonitrile under microwave heating for 1 h at 160°C. Pharmacol. activity of I was evaluated using a HTRF assay and Trx-6xHis-Bcl6 derived from the human Bcl6 BRB domain from which II demonstrated a pIC50 value of 7.38 μM. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

The Article related to quinolinone diamino derivative preparation inhibitor bcl6 inhibitor cancer, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Two Hetero Atoms and other aspects.Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Sato, Takeru; Sasaki, Muneo; Ikeda, Yoshiyuki; Kimoto, Masaki published an article in 2013, the title of the article was Preparation and estimation of super water-repellent film coated by silica and acrylic-silicon containing active methylene group.Formula: C13H20O4 And the article contains the following content:

In acrylic silicone (M-CAS) solution containing active methylene group, silica micro particles were synthesized by addition of tetraethoxysilane. When this composite film coated on a glass substrate, the water contact angle showed 120°. Furthermore, the film which the hexamethyldisilazane as silane coupling agent was added to together, showed the contact angle of 155°. However, as a result of the wear test, the contact angle of the composite film reduced to 60°. When the crosslinking agent was added in reaction solution and was cured by UV irradiation, contact angle of the coating film showed 130°. Even through wear test, the UV-irradiation-curing composite film maintained its contact angle ca.100°. Repeated coating and UV irradiation-curing formed the super water – repellent film, and even through wear test it maintained excellent water – repellency, its contact angle being reduced only to 130°C. The experimental process involved the reaction of 2,2-Dimethylpropane-1,3-diyl bis(2-methylacrylate)(cas: 1985-51-9).Formula: C13H20O4

The Article related to acrylic silicon active methylene crosslinking silica particle water repellent, Coatings, Inks, and Related Products: Acrylic and Water-Sol (Electrophoretic) Resin Coatings and other aspects.Formula: C13H20O4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 8, 2021, Crew, Andrew P.; Wang, Jing; Berlin, Michael; Dragovich, Peter; Chen, Huifen; Staben, Leanna published a patent.Synthetic Route of 882518-89-0 The title of the patent was Preparation of pyridazinamine derivatives as modulators of SMARCA2 and BRM target proteins and associated methods of use. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of SMARCA2 or BRM (target protein). The disclosure is directed to bifunctional compounds of formula I, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Compounds of formula I wherein ULM is a small mol. E3 ubiquitin ligase binding moiety that binds a Von Hippel-Lindau E3 ubiquitin ligase; L is a bond and a chem. linker; PTM is a small mol. comprising a SMARCA2 protein targeting moiety; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. The disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the disclosure. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their SMARCA2 and BRM modulatory activity. From the assay, it was determined that compound II exhibited DC50 value of ≥ 30 nM and Dmax value of > 75%. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Synthetic Route of 882518-89-0

The Article related to pyridazine preparation smarca2 brm protein modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Synthetic Route of 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 6, 2020, Crew, Andrew P.; Wang, Jing; Berlin, Michael; Dragovich, Peter; Chen, Huifen; Staben, Leanna published a patent.Application of 882518-89-0 The title of the patent was Preparation of pyridazinamine derivatives as modulators of SMARCA2 and BRM target proteins and associated methods of use. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of SMARCA2 or BRM (target protein). The disclosure is directed to bifunctional compounds of formula I, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Compounds of formula I wherein ULM is a small mol. E3 ubiquitin ligase binding moiety that binds a Von Hippel-Lindau E3 ubiquitin ligase; L is a bond and a chem. linker; PTM is a small mol. comprising a SMARCA2 protein targeting moiety; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. The disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the disclosure. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their SMARCA2 and BRM modulatory activity. From the assay, it was determined that compound II exhibited DC50 value of ≥ 30 nM and Dmax value of > 75%. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Application of 882518-89-0

The Article related to pyridazine preparation smarca2 brm protein modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Application of 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 30, 2018, Osawa, Tsutomu; Wakasugi, Masahiro; Kizawa, Tomoko; Borovkov, Victor; Inoue, Yoshihisa published an article.Reference of (R)-Methyl 3-hydroxybutanoate The title of the article was Enantio-differentiating hydrogenation of alkyl 3-oxobutanoates over tartaric acid-modified Ni catalyst: Enthalpy-entropy compensation effect as a tool for elucidating mechanistic features. And the article contained the following:

The enantio-differentiating hydrogenations of a series of alkyl 3-oxobutanoates were carried out at the temperatures ranging from 333 to 393K over the (R,R)-tartaric acid-modified Ni catalyst prepared from com. available Ni powder to achieve high enantiomeric excesses of 91-94%. It was demonstrated that the enantio-selectivity was not a simple function of the reaction temperature, being enhanced in the low temperature region to reach a maximum at 363-373K and then decreased at higher temperatures Nevertheless, all the differential enthalpies and entropies of activation calculated from the enantiomer ratios in the low and high temperature regions compensated with each other, indicating the same enantio-differentiation mechanism over the entire temperature range. A plausible enantio-differentiation mechanism explaining the effects of hydrogenation temperature on the enantio-selectivity is proposed. The experimental process involved the reaction of (R)-Methyl 3-hydroxybutanoate(cas: 3976-69-0).Reference of (R)-Methyl 3-hydroxybutanoate

The Article related to alkyl oxobutanoate hydrogenation mechanism kinetics thermodn, Physical Organic Chemistry: Oxidation-Reduction, Including Dehydrogenation and Hydrogenolysis and other aspects.Reference of (R)-Methyl 3-hydroxybutanoate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 18, 2022, Lin, Zhaiwei; Cui, Baicheng published a patent.Name: Ethyl 3-fluoro-2-methylbenzoate The title of the patent was Preparation of pyridazinone derivative and its application for preventing, alleviating or treating viral infection. And the patent contained the following:

The present invention relates to the preparation of pyridazinone derivative and its application for preventing, alleviating or treating viral infection. In particular, the pyridazinone derivatives I (wherein, R1 = H or -C(=O)Y1, -C(=O)-O-Y1, -(CH2)-O-(C=O)-Y1, -(CH2)-O-(C=O)-OY1, -(CHCH3)-O-(C=O)-Y1 and -(CHCH3)-O-(C=O)-O-Y1; Y1 is optionally substituted C1-10 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, monosubstituted amino, disubstituted amino, and -C(R*)2NHR**; and each R* and R** is independently hydrogen or optionally substituted C1-6 alkyl; R2 and R3 = H, D, C1-6 alkyl, -C(O)-C1-6 alkyl, halogen, -CF3, -CN, -COOR*, -OR*, (CH2)qNR*R**, -C(O)-NR*R**; R4 is (un)substituted (hetero)arylmethyl). On further, ( R2 and R3 can be connected to form a ring to form an optionally substituted cycloalkyl, an optionally substituted heterocyclyl and an optionally substituted cycloalkenyl; R* and R** are independently H and optionally substituted C1-6 alkyl; q is 0-6; R7 and R8 are optionally substituted aryl, and optionally substituted heteroaryl; wherein the substituents are independent C1-6 alkyl, -C(O)-C1-6 alkyl, halogen, -CF3, – CN, -COOR*, -OR*, -(CH2)qNR*R**,-C(O)-NR*R**; R* and R** = H, D and optionally substituted C1-6 alkyl, q is 0-6; R7 and R8 can be linked to form the structure III; n and m = 0-3, Q = CR*R**, NR*, O, S, SO, SO2; and R* and R** are independently H and optionally substituted C1-6 alkyl) and its pharmaceutically acceptable salts, solvates, hydrates, polycrystals, prodrugs, co-crystals, tautomers, and stereoisomers thereof was prepared More specifically, the compounds of the present invention can be used as anti-influenza drugs with CEN inhibitory effect. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Name: Ethyl 3-fluoro-2-methylbenzoate

The Article related to pyridazinone derivative preparation viral infection treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Name: Ethyl 3-fluoro-2-methylbenzoate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 5, 2022, Wang, Yonggang; Lin, Zhaiwei; Hu, Shuanghua published a patent.Safety of Ethyl 3-fluoro-2-methylbenzoate The title of the patent was Preparation of pyridazinone derivatives and its application thereof. And the patent contained the following:

The present invention relates to the preparation of pyridazinone derivatives and its application thereof. In particular, pyridazinone derivative I (wherein, R1 is H, optionally substituted phosphate group or -C(=O)Y1, -C(=O)-O-Y1, -(CH2)-O-(C=O)-Y1, (CH2)- O-(C=O)-O-Y1, -(CHCH3)-O-(C=O)-Y1 and -(CHCH3)-O-(C=O)-O-Y1; Y1 is optionally substituted C1-10 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, etc.; R2 and R3 can be optionally independently H, C1-6 alkyl, -C(O)-C1-6 alkyl, halogen, -CF3, -CN, etc.; R4 is (R7)(R8)CH- (here, R7 and R8 are are optionally substituted aryl, and optionally substituted heteroaryl; wherein the substituents are independent C1-6 alkyl, -C(O)- C1-6 alkyl, etc.)). Further, (or II (here, R9, R10 are optionally substituted aryl, and optionally substituted heteroaryl; wherein the substituents are independent C1-6 alkyl, -C(O)- C1-6 alkyl, C1-6 haloalkyl, halogen, -CF3, etc.; R11 is H, C1-3 alkyl, C1-3 haloalkyl or C1-3 alkoxy); R7 and R8 can be linked to form a ring structure III (where n and m can be independently 0-3, Q is CR*R**, NR*, O, S, SO, SO2; R* and R** are independently H and optionally substituted C1-6 alkyl); R5 and R6 are independently selected from F, CH3 and CF3, and R5 and R6 are not selected as CH3 at the same time) and its pharmaceutically acceptable salts, solvates, hydrates, N-oxides, polycrystals, prodrugs, co-crystals, tautomers, stereoisomers or their mixtures, isotopically labeled derivatives were prepared The inventive compounds of the present invention can be used as anti-influenza drugs having CEN (cap-dependent endonuclease) inhibition. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Safety of Ethyl 3-fluoro-2-methylbenzoate

The Article related to pyridopyridazine dione derivative preparation antiinfluenza drug, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Safety of Ethyl 3-fluoro-2-methylbenzoate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 18, 1994, Maier, Franz Karl; Ebert, Wolfgang; Lee-Vaupel, Mary; Gries, Heinz; Conrad, Juergen published a patent.Name: Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of meso-tetraphenylporphyrin complexes as diagnostic and therapeutic agents. And the patent contained the following:

Title complexes comprising I [R1 = VCOA, VSO2A, VP(O)A2, NECH2COA; A = OH, OR4, NR5R6; E = acyl, alkylsulfonyl, carboxyalkyl, etc.; R2 = groups cited for R1 and R3; R3 = H, halo, alky; R4 = alkyl, CH2Ph; R5,R6 = H, hydrocarbyl, aryl(alkyl); NR5R6 = heterocyclyl; V = (un)substituted alkylene] and an ion of elements having Z = 21-32, 38, 39, 42-51, and 58-83 were prepared Thus, Mn3+ {5,10,15,20-tetrakis[4-(carboxymethoxy)phenyl]porphyrin} chloride was prepared in 3 steps from 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin. Physiol. compatibility and relaxivity data for 2 I were given. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Name: Methyl 2-(3-formylphenyl)acetate

The Article related to mesotetraphenylporphyrin complex preparation diagnostic therapeutic, Physical Organic Chemistry: Oxidation-Reduction, Including Dehydrogenation and Hydrogenolysis and other aspects.Name: Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 18, 2022, Lin, Zhaiwei; Cui, Baicheng published a patent.Formula: C10H11FO2 The title of the patent was Preparation of pyridazinone derivatives and its application as anti-influenza drugs with CEN inhibitory effect. And the patent contained the following:

The present invention relates to the preparation of pyridazinone derivatives and its application as anti-influenza drugs with CEN inhibitory effect. In particular, the pyridazinone derivative I (wherein, R1 = H or -C(=O)Y1, -C(=O)-O-Y1, -(CH2)-O-(C=O)-Y1 etc.; Y1 = optionally substituted C1-10 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, -C(R* )2NHR** etc., and each R* and R** = independently hydrogen or optionally substituted C1-6 alkyl; R2 and R3 = independently H, D, C1-6 alkyl, -C(O)- C1-6 alkyl, halogen, -OR* etc.; R2 and R3 can be connected to form a ring to form an optionally substituted cycloalkyl, an optionally substituted heterocyclyl and an optionally substituted cycloalkenyl; R* and R** = independently H and optionally substituted C1-6 alkyl; q = 0-6). Further, (R4 = R6 and R7 substituted isobutane, where R6 and R7 are optionally substituted aryl groups and optionally substituted heteroaryl groups; wherein the substituents are independently C1-6 alkyl, -CN, -COOR* etc., where R* and R** = independently H, D and optionally substituted C1-6 alkyl; q = 0-6; R6 and R7 can be linked to form a compound II (wherein, m and n = independently 0-3, Q = CR*R**, NR*, O, S, SO, SO2; R* and R** = independently H, D and optionally substituted C1-6 alkyl); R5 = optionally substituted cycloalkyl, optionally substituted heterocyclyl and optionally substituted cycloalkenyl, such as a 6-membered ring, the ring may be carbocycle or O, N containing heterocycle) or its pharmaceutically acceptable salts, solvates, including hydrates, polymorphs, prodrugs, co-crystals, tautomers, stereoisomers were prepared The inventive compounds can be used as anti-influenza drugs having CEN inhibitory action. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Formula: C10H11FO2

The Article related to pyridazinone derivative preparation antiinfluenza drug cen inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Formula: C10H11FO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics